{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:04:10Z","timestamp":1777421050676,"version":"3.51.4"},"reference-count":110,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2015,7,2]],"date-time":"2015-07-02T00:00:00Z","timestamp":1435795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:p>Objective: To review the literature for the treatment of hepatitis C virus (HCV) genotype 1 in certain populations of patients that require further considerations before therapy initiation. Data Sources: A systematic electronic literature search using the MEDLINE database was performed using the search terms hepatitis C, chronic hepatitis C, drug therapy, end stage liver disease, liver transplantation, HIV, hepatitis B, African Americans, renal insufficiency, obesity, pregnancy, and pediatrics. Study Selection and Data Extraction: English language studies from January 1985 to March 2015 were considered. Additional references were identified from ongoing trials obtained from clinicaltrials.gov, conference proceedings, online databases, and citations in relevant review articles. Data Selection: Direct-acting antivirals are first-line recommendations for the treatment of HCV genotype 1 infection, and these include combinations of sofosbuvir, simeprevir, ledipasvir\/sofosbuvir, ombitasvir\/paritaprevir\/ritonavir plus dasabuvir, and ribarvirin. Historical and clinical data focusing on the treatment of HCV with these agents in the following populations were selected: decompensated cirrhosis, post-liver transplant, HIV, African Americans, obesity, hepatitis B coinfection, renal impairment, pregnancy, and pediatrics. Conclusion: Depending on the population studied, clinicians must consider differences in efficacy outcomes, potential drug interactions, and adverse effects that patients may experience.<\/jats:p>","DOI":"10.1177\/1060028015592015","type":"journal-article","created":{"date-parts":[[2015,7,3]],"date-time":"2015-07-03T10:54:52Z","timestamp":1435920892000},"page":"1015-1030","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection"],"prefix":"10.1177","volume":"49","author":[{"given":"Kimberly A.","family":"Toussaint-Miller","sequence":"first","affiliation":[{"name":"Temple University School of Pharmacy, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Andres","sequence":"additional","affiliation":[{"name":"Temple University School of Pharmacy, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,7,2]]},"reference":[{"key":"bibr1-1060028015592015","unstructured":"Centers for Disease Control and Prevention. Hepatitis C information. 2015. http:\/\/www.cdc.gov\/hepatitis\/HCV\/. Accessed March 2015."},{"key":"bibr2-1060028015592015","unstructured":"World Health Organization. Hepatitis C. 2003. http:\/\/www.who.int\/csr\/disease\/hepatitis\/hepC\/. Accessed March 2015."},{"key":"bibr3-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22759"},{"key":"bibr4-1060028015592015","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.82a.14004"},{"key":"bibr5-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis361"},{"key":"bibr6-1060028015592015","unstructured":"Recommendations for testing, managing, and treating hepatitis C. AASLD\/IDSA\/IAS\u2013USA, 2015. http:\/\/www.hcvguidelines.org\/. Accessed April 2015."},{"key":"bibr7-1060028015592015","unstructured":"Hepatitis Support Project. A brief history of hepatitis C. 2015. http:\/\/hcvadvocate.org\/hepatitis\/. Accessed May 2015."},{"key":"bibr8-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"bibr9-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"bibr10-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.02.039"},{"key":"bibr11-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12230"},{"key":"bibr12-1060028015592015","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-6-200809160-00006"},{"key":"bibr13-1060028015592015","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-10-200711200-00003"},{"key":"bibr14-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.12.028"},{"key":"bibr15-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707615"},{"key":"bibr16-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23340"},{"key":"bibr17-1060028015592015","unstructured":"Intron-A (pegylated interferon alfa-2a). Product information. Whitehouse Station, NJ: Merck & Co; 1986."},{"key":"bibr18-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000121"},{"key":"bibr19-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280333"},{"key":"bibr20-1060028015592015","volume-title":"Paper presented at: The 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)","author":"Flamm SL"},{"key":"bibr21-1060028015592015","unstructured":"Olysio (simeprevir) Product information. Titusville, NJ: Janssen Therapeutics; 2013."},{"key":"bibr22-1060028015592015","volume-title":"Paper presented at: The 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)","author":"Modi AA"},{"key":"bibr23-1060028015592015","unstructured":"OPTN\/SRTR Annual Data Report, 2012. http:\/\/srtr.transplant.hrsa.gov\/annual_reports\/2012\/pdf\/03_liver_13.pdf\/. Accessed April 2015."},{"key":"bibr24-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)91129-R"},{"key":"bibr25-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2002.35781"},{"key":"bibr26-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.32418"},{"key":"bibr27-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.04.023"},{"key":"bibr28-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.02.011"},{"key":"bibr29-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.041"},{"key":"bibr30-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(91)90814-R"},{"key":"bibr31-1060028015592015","unstructured":"Victrelis (boceprevir). Product information. Whitehouse Station, NJ: Merck & Co; 2011."},{"key":"bibr32-1060028015592015","unstructured":"Incivek (telaprevir). Product information. Cambridge, MA: Vertex Pharmaceuticals."},{"key":"bibr33-1060028015592015","volume-title":"Paper presented at: The 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)","author":"Reddy KR"},{"key":"bibr34-1060028015592015","volume-title":"Paper presented at: The 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)","author":"Pungpapong S"},{"key":"bibr35-1060028015592015","volume-title":"Paper presented at: The 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)","author":"Sulkowski MS"},{"key":"bibr36-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12856."},{"key":"bibr37-1060028015592015","unstructured":"Hepatitis C drug interactions. The University of Liverpool. 2015. http:\/\/www.hep-druginteractions.org\/Interactions\/. Accessed May 2015."},{"key":"bibr38-1060028015592015","unstructured":"Safety and efficacy of new DAA-based therapy for hepatitis C post-transplant: interval results from the HCV-TARGET longitudinal, observational study. American Association for the Study of Liver Diseases, 2014. http:\/\/www.natap.org\/2014\/AASLD\/AASLD_19.html\/. Accessed April 2015."},{"key":"bibr39-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408921"},{"key":"bibr40-1060028015592015","unstructured":"Viekira Pak (Ombitasvir\/paritaprevir\/ritonavir plus dasabuvir). Product information. North Chicago, IL: AbbVie Inc; 2014."},{"key":"bibr41-1060028015592015","unstructured":"Harvoni (ledipasvir\/sofosbuvir). Product information. Forest City, CA: Gilead Sciences; 2014."},{"key":"bibr42-1060028015592015","unstructured":"Sovaldi (sofosbuvir). Product information. Forest City, CA: Gilead Sciences; 2014."},{"key":"bibr43-1060028015592015","unstructured":"Centers for Disease Control and Prevention. HIV and viral hepatitis. 2014. https:\/\/www.cdc.gov\/hiv\/. Accessed May 2015."},{"key":"bibr44-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107053450107"},{"key":"bibr45-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(97)80001-3"},{"key":"bibr46-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300409"},{"key":"bibr47-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1086\/321909"},{"key":"bibr48-1060028015592015","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-9-201305070-00604"},{"key":"bibr49-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2004.20.1293"},{"key":"bibr50-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2007.00962.x"},{"key":"bibr51-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.07.006"},{"key":"bibr52-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21757"},{"key":"bibr53-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1042\/CS20080532"},{"key":"bibr54-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.59.081906.081110"},{"key":"bibr55-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200403260-00007"},{"key":"bibr56-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282170a9d"},{"key":"bibr57-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1373"},{"key":"bibr58-1060028015592015","volume-title":"Paper presented at: The 22nd Conference on Retroviruses and Opportunistic Infections","author":"Naggie S"},{"key":"bibr59-1060028015592015","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 2015. http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf\/. Accessed May 2015."},{"key":"bibr60-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1328"},{"key":"bibr61-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu046"},{"key":"bibr62-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61036-9"},{"key":"bibr63-1060028015592015","volume-title":"Paper presented at: The 22nd Conference on Retroviruses and Opportunistic Infections","author":"Del Bello D"},{"key":"bibr64-1060028015592015","volume-title":"Paper presented at: The 22nd Conference on Retroviruses and Opportunistic Infections","author":"Gilmore J"},{"key":"bibr65-1060028015592015","volume-title":"Paper presented at: The 22nd Conference on Retroviruses and Opportunistic Infections","author":"Grant JL"},{"key":"bibr66-1060028015592015","volume-title":"Paper presented at: The 22nd Conference on Retroviruses and Opportunistic Infections","author":"Marks K"},{"key":"bibr67-1060028015592015","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i11.2955"},{"key":"bibr68-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12421"},{"key":"bibr69-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23190"},{"key":"bibr70-1060028015592015","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-10-200605160-00004"},{"key":"bibr71-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.19582"},{"key":"bibr72-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401001"},{"key":"bibr73-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000225689.60335.44"},{"key":"bibr74-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e318238352b"},{"key":"bibr75-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.045"},{"key":"bibr76-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402338"},{"key":"bibr77-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"bibr78-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401561"},{"key":"bibr79-1060028015592015","volume-title":"Presented at: Presented at: 65th Annual American Association for the Society of Liver Diseases Conference","author":"Jeffers LJ"},{"key":"bibr80-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V11101896"},{"key":"bibr81-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2007.00868.x"},{"key":"bibr82-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2007.11.003"},{"key":"bibr83-1060028015592015","doi-asserted-by":"crossref","unstructured":"Ozdemir A, Yalinbas B, Selamet U, Relationship between iron replacement and hepatic functions in hepatitis C virus-positive chronic haemodialysis patients. 2005;10:433-437.","DOI":"10.1111\/j.1440-1797.2005.00474.x"},{"key":"bibr84-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"bibr85-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"bibr86-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"bibr87-1060028015592015","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-11-201312030-00005"},{"key":"bibr88-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2006.12.010"},{"key":"bibr89-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2005.00680.x"},{"key":"bibr90-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.12.016"},{"key":"bibr91-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1177\/039139880803100404"},{"key":"bibr92-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm724"},{"key":"bibr93-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e318180803a"},{"key":"bibr94-1060028015592015","unstructured":"Gilead Sciences. Sofosbuvir plus ribavirin in subjects with HCV infection and renal insufficiency. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01958281. Accessed May 2015."},{"key":"bibr95-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.08.005"},{"key":"bibr96-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.213553"},{"key":"bibr97-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00479-3"},{"key":"bibr98-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.05.007"},{"key":"bibr99-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22865"},{"key":"bibr100-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.3.572"},{"key":"bibr101-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1542\/peds.102.2.355"},{"key":"bibr102-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1086\/497695"},{"key":"bibr103-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1542\/peds.101.3.481"},{"key":"bibr104-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1086\/345908"},{"key":"bibr105-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1086\/497141"},{"key":"bibr106-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-199404000-00005"},{"key":"bibr107-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1542\/peds.89.4.707"},{"key":"bibr108-1060028015592015","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i44.7880"},{"key":"bibr109-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1086\/497141"},{"key":"bibr110-1060028015592015","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e318258328d"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028015592015","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028015592015","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028015592015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:52Z","timestamp":1777374952000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028015592015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,2]]},"references-count":110,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1177\/1060028015592015"],"URL":"https:\/\/doi.org\/10.1177\/1060028015592015","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,2]]}}}